{Reference Type}: Journal Article
{Title}: Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience.
{Author}: Orbach D;Van Noesel MM;Brennan B;Corradini N;Alaggio R;Ben Arush M;Schoot RA;Berlanga P;Zanetti I;Hjalgrim LL;Di Corti F;Ramirez G;Casanova M;Ferrari A;
{Journal}: Pediatr Blood Cancer
{Volume}: 69
{Issue}: 10
{Year}: Oct 2022
{Factor}: 3.838
{DOI}: 10.1002/pbc.29882
{Abstract}: The European pediatric Soft tissue sarcoma Study Group analyzed all children with epithelioid hemangioendothelioma prospectively registered in the NRSTS-05 (EUDRACT 2005-001139-31) and in MTS-2008 (NCT00379457) studies: 10 patients with localized and one with metastatic disease. Median age was 14.3 years (range, 9.0-18.8). Local therapy was initial primary surgery in seven cases, and five patients received systemic therapy. No patients received radiotherapy. After a median follow-up of 50 months (range, 6-176) for living patients, nine patients remain alive off therapy and two died. Five-year progression free and overall survivals are, respectively, 77.1% (95% confidence interval [CI]: 34.5-93.9) and 74.1% (95% CI: 28.1-93.0).